|This research had 2 parts; the first part was a cross-sectional descriptive study to evaluate the effects of drug strength, gender, age, body mass index and duration of administration of antiretroviral agent on dyslipidemia status in HIV/AIDs patients receiving GPO-VIR S. This was conducted at Infectious Clinic, Sappasittiprasong Hospital, Ubon Rajathanee during October 2006. The result showed that the strength of GPO-VIR S was correlated with the level of LDL-cholesterol and non HDL-cholesterol ( = 24.82, p-value = 0.001, = 31.03, p-value = 0.011 respectively). The strength ( = 39.91, p-value < 0.001) and duration of GPO-VIR S administration ( = 0.53, p-value = 0.016) were correlated with total cholesterol. Gender ( = 4.85, p-value = 0.001), body mass index ( = -0.62, p-value = 0.012) and duration of drug administration ( = 0.53, p-value = 0.016) were correlated with the level of HDL-cholesterol. Age ( = 0.05, p-value = 0.020), body mass index ( = 0.13, p-value = 0.016) and duration of drug administration ( = 0.03, p-value = 0.005) were correlated with triglyceride level.
The second part was a randomized control-group pretest-posttest study with an aim to determine the effects of an education program using the health belief model on dyslipidemia status in HIV/AIDs patients. The sample were HIV/AIDs patients receiving GPO-VIR S at Infectious Clinic, Supprasitthiprasong Hospital with Hyperlipidemia status. The data was collected between November 2006 - February 2007. The subjects were randomly selected and divided into the experimental group (36 patients) and the control group (36 patients). The former group of subjects received education program 2 times while the control group received a routine care procedure from staffs and nurses. The result showed that in the first and second visits, the experimental group positively changed their knowledge and health perceived behavior significantly higher than those in the pretest period and those in the control group (p-value < 0.001). On the first visit, consuming behavior and exercising behavior of the experimental group did not significantly differ from the control group. On the second visit, consuming behavior and exercising behavior of the experimental group were significantly higher than the control group
(p-value = 0.048, 0.032 respectively). In addition, smoking behavior of the experimental group did not differ from pretest period and the control group in both visits. However, lipid level of the experimental group did not differ from pretest period and the control group.
In conclusion, these results indicated that the education program significantly improved knowledge, health perceived behavior, consuming behavior and exercising behavior. However, this program could not reduce their lipid level because the dyslipidemia status in the HIV/AIDs patients receiving GPO-VIR S was possibly its side effects. Therefore, combination of antihyperlipidemia agents and therapeutic lifestyle change may be another option to be considered.